Javelin’s Intranasal Morphine Meets Phase III Primary Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
Morphine delivered using Javelin’s proprietary technology could offer simpler, effective alternative to other postoperative opioids, firm says.
You may also be interested in...
Javelin’s Dyloject On Track For 1H 2009 NDA Filing; PMI-150 Needs Additional Efficacy Study
Following Dec. U.K. Dyloject launch, firm plans to market the NSAID in other European markets during the second half of next year.
Javelin’s Dyloject On Track For 1H 2009 NDA Filing; PMI-150 Needs Additional Efficacy Study
Following Dec. U.K. Dyloject launch, firm plans to market the NSAID in other European markets during the second half of next year.
Javelin Gets FDA Guidance On Intranasal Ketamine For Pain
Company plans to file via the 505(b)(2) pathway for military and emergency civilian use in 2008.